Strategies for HIV-1 suppression through key genes and cell therapy

Alyona Sorokina; Elizaveta Anchakova; Erdem Dashinimaev

doi:10.3389/fmed.2023.1259995

Strategies for HIV-1 suppression through key genes and cell therapy

Front Med (Lausanne). 2023 Nov 29:10:1259995. doi: 10.3389/fmed.2023.1259995. eCollection 2023.

Authors

Alyona Sorokina¹, Elizaveta Anchakova^{1

2}, Erdem Dashinimaev^{1

2}

Affiliations

¹ Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Pirogov Russian National Research Medical University, Moscow, Russia.
² Moscow Institute of Physics and Technology (State University), Dolgoprudny, Russia.

Abstract

Human immunodeficiency virus type 1 (HIV-1) remains a significant challenge for global public health as limited therapeutic options are available for HIV-infected individuals receiving combination antiretroviral therapy. Additionally, individuals with HIV-1/acquired immunodeficiency syndrome (AIDS) complications have a reduced life expectancy. In recent decades, gene and cell-based strategies have shown promise in achieving a functional cure for HIV-1 infection. The outcomes of therapies with patients in Berlin and London have led to moderate optimism for a highly effective HIV-1 treatment. This review categorizes current strategies for HIV-1 treatment into RNA- and antibody-based therapies, cell and genome editing approaches, and methods for eradicating latent reservoirs. These findings demonstrate how the use of various anti-HIV-1 agents enhances our understanding of HIV-1 infection and may provide important insights for potential HIV-1 treatment.

Keywords: AIDS; CCR5; CRISPR/Cas9 findings number; HIV-1; cART.

Publication types

Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This publication was supported by a grant No. 075-15-2019-1789 from the Ministry of Science and Higher Education of the Russian Federation allocated to the Center for Precision Genome Editing and Genetic Technologies for Biomedicine.